Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension
This Study is
No Longer Enrolling
Details
Age
Adult
Eligibility
Age 18-80 Diagnosis: ALS Onset of ALS symptoms less than 24 months ago Able to swallow pills
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
Study ID
Protocol Number: 22-0037
More information available at ClinicalTrials.gov: NCT05237284
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers